抗MERS-CoV小分子化合物的研究进展  

Small molecular agents against MERS-CoV infection

作　　者：曾晓云[1,2] 陆路[3] 姜世勃[3] 刘叔文[1,2] 

机构地区：[1]南方医科大学药学院,广东广州510515 [2]南方医科大学广东省新药筛选重点实验室,广东广州510515 [3]复旦大学基础医学院,医学分子病毒学教育部/卫生部重点实验室,上海200032

出　　处：《药学学报》2015年第12期1520-1526,共7页Acta Pharmaceutica Sinica

摘　　要：中东呼吸系统综合征冠状病毒(Middle East respiratory syndrome-coronavirus,MERS-CoV)引起的MERS流行,其死亡率高达35%。自被发现以来,大多数MERS-CoV感染病例主要发生在中东地区。而2015年MERS疫情在韩国严重爆发,引起了全球的关注。目前对于MERS-Co V的感染尚无经临床上验证有效的抗病毒药物。现今抗MERS-CoV候选药物主要包括单克隆抗体、多肽、小分子化合物等。其中,小分子化合物因其具有合成方便、价格低廉、性质稳定等优势值得进一步的开发。本文综述了抗MERS-CoV小分子化合物的研究进展。Middle East respiratory syndrome coronavirus （MERS-CoV） has caused outbreaks of SARS-like disease with 35% case-fatality rate, mainly in the Middle East. A more severe outbreak of MERS occurred recently in the Republic of Korea, where 186 people contracted the infections, causing great concern worldwide. So far, there has been no clinically available drug for the treatment of MERS-CoV infection. The potential drugs against MERS-CoV mainly consist of monoclonal antibodies, peptides and small molecular agents. Small molecular agents have an advantage of easier synthesis, lower cost in production and relatively higher stability. There is better chance for those candidates to gain a quick development. This article reviews the progress of developing small molecular MERS-CoV agents.

关 键 词：中东呼吸系统综合征冠状病毒 药物靶点 小分子化合物 

分 类 号：R916[医药卫生—药学]